IN VIVO EVALUATION OF ANTICANCER ACTIVITY OF NOVEL 6-FLUORO-3-(PIPERIDIN-4-YL) BENZO [D] ISOXAZOLE DERIVATIVES AGAINST EHRLICH ASCITES CARCINOMA IN MICE
Author(s): Sharath Chandra SP and Periyapatna Vishwaprakash Mahadimane
Abstract
The aim of the present study is to investigate the anticancer properties of newly synthesized benzisoxazole derivatives (S1�?¢�?�?��?S4) in Swiss albino mice against Ehrlich Ascites Carcinoma (EAC) cell line. The anticancer activity of synthesized molecules and 5 fluorouracil was investigated against Ehrlich ascites carcinoma (EAC) tumor in mice at dose of 20 mg/kg body weight (orally and intra peritoneally). Acute oral toxicity studies were performed to ensure the safety of the molecules. EAC cells were injected (i.p.) into ninety six mice (divided into 6 equal groups), and after a one�?¢�?�?��?day incubation period, both molecules and drug was administered to the mice daily for 14 days. On day 15, 6 animals in each group were sacrificed for observation of anticancer activity like mean increase in body weight and viability of cancer cells. Whereas mean survival rate and percentage of increase in life span was conducted for a period of 6 weeks. Administration of the synthesized molecules resulted in a significant (p < 0.05) decrease in tumor volume and viable cell count, and increased non�?¢�?�?��?viable cell count and mean survival time, resulting in increase of the life span of the EAC�?¢�?�?��?bearing mice. The results indicate that the synthesized molecules (S2 and S3) exhibited significant anticancer activity comparable to that of standard drug 5 fluorouracil.
Share this article
International Journal of Bioassays is a member of the Publishers International Linking Association, Inc. (PILA), CROSSREF and CROSSMARK (USA). Digital Object Identifier (DOI) will be assigned to all its published content.
